[Intracellular disorders in myocardium of dogs during cardiogenic shock and possibilities of their correction].
Dizhe
A A
AA
Levshankov
A I
AI
Krasovskaia
I E
IE
Dizhe
G P
GP
D000067956:Adenylyl Cyclase Inhibitors; D000262:Adenylyl Cyclases / Q000378:metabolism; D000818:Animals; D007611:Aprotinin / Q000494:pharmacology / Q000627:therapeutic use; D002118:Calcium / Q000378:metabolism*; D002302:Cardiac Output / Q000187:drug effects*; D004195:Disease Models, Animal; D004285:Dogs; D004791:Enzyme Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D006321:Heart / Q000187:drug effects / Q000503:physiopathology*; D006439:Hemodynamics / Q000187:drug effects; D008982:Molybdenum / Q000494:pharmacology / Q000627:therapeutic use; D009206:Myocardium / Q000201:enzymology / Q000378:metabolism*; D047428:Protein Kinase Inhibitors; D011494:Protein Kinases / Q000378:metabolism; D012519:Sarcoplasmic Reticulum / Q000201:enzymology / Q000378:metabolism; D012770:Shock, Cardiogenic / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism / Q000503:physiopathology*; D016277:Ventricular Function, Left / Q000187:drug effects
D000067956:Adenylyl Cyclase Inhibitors; D004791:Enzyme Inhibitors; D047428:Protein Kinase Inhibitors; D008982:Molybdenum; D007611:Aprotinin; D011494:Protein Kinases; D000262:Adenylyl Cyclases; C022175:ammonium molybdate; D002118:Calcium